Abstract
Athymic mice, injected with A375 human melanoma cells, were treated daily with intraperitoneal injections of adenosine 5′-triphosphate (ATP). The tumour volume and animal weight were measured over the course of the experiment and the final tumour nodule weight was measured at the end of the experiment. Tumour volume decreased by nearly 50% by 7 weeks in treated mice. Weight loss in untreated animals was prevented by ATP. Histological examination of the excised tumour nodules showed necrosis in the ATP-treated tumours only. The presence of P2Y1 and P2X7 receptors, previously proposed as extracellular targets for melanoma treatment with ATP, were demonstrated in the excised specimens by immunohistochemistry. This paper provides further support for the use of ATP as a treatment for melanoma.
Similar content being viewed by others
References
Grin-Jorgensen CM, Rigel DS, Friedman RJ (1992) The world-wide incidence of malignant melanoma. In: Balch CM (ed) Cutaneous melanoma. Lippincott Williams & Wilkins, Philadelphia, pp 27–39
Hara M, Toyoda M, Yaar M, Bhawan J, Avila EM, Penner IR, Gilchrest BA (1996) Innervation of melanocytes in human skin. J Exp Med 184:1385–1395. doi:10.1084/jem.184.4.1385
Hu DN, Woodward DF, McCormick SA (2000) Influence of autonomic neurotransmitters on human uveal melanocytes in vitro. Exp Eye Res 71:217–224. doi:10.1006/exer.2000.0869
Brocker EB, Magiera H, Herlyn M (1991) Nerve growth and expression of receptors for nerve growth factor in tumors of melanocyte origin. J Invest Dermatol 96:662–665. doi:10.1111/1523-1747.ep12470585
Burnstock G (2007) Purine and pyrimidine receptors. Cell Mol Life Sci 64:1471–1483. doi:10.1007/s00018-007-6497-0
Sneddon P, Burnstock G (1984) Inhibition of excitatory junction potentials in guinea-pig vas deferens by α, β-methylene-ATP: further evidence for ATP and noradrenaline as cotransmitters. Eur J Pharmacol 100:85–90. doi:10.1016/0014-2999(84) 90318-2
Burnstock G (1988) Sympathetic purinergic transmission in small blood vessels. Trends Pharmacol Sci 9:116–117. doi:10.1016/0165-6147(88) 90185-X
Hoyle CHV, Burnstock G (1993) Postganglionic efferent transmission to the bladder and urethra. In: Maggi C (ed) The autonomic nervous system, vol. 3. Nervous control of the urogenital system. Harwood, Switzerland, pp 349–383
Burnstock G (2004) Cotransmission. Curr Opin Pharmacol 4:47–52. doi:10.1016/j.coph.2003.08.001
Burnstock G, Knight GE (2004) Cellular distribution and functions of P2 receptor subtypes in different systems. Int Rev Cytol 240:31–304. doi:10.1016/S0074-7696(04) 40002-3
Merighi S, Varani K, Gessi S, Cattabriga E, Iannotta V, Ulouglu C, Leung E, Borea PA (2001) Pharmacological and biochemical characterization of adenosine receptors in the human malignant melanoma A375 cell line. Br J Pharmacol 134:1215–1226. doi:10.1038/sj.bjp. 0704352
Slater M, Scolyer RA, Gidley-Baird A, Thompson JF, Barden JA (2003) Increased expression of apoptotic markers in melanoma. Melanoma Res 13:137–145. doi:10.1097/00008390-200304000-00005
White N, Butler PEM, Burnstock G (2005) Human melanomas express functional P2X7 receptors. Cell Tissue Res 321:411–418. doi:10.1007/s00441-005-1149-x
White N, Ryten M, Clayton E, Butler P, Burnstock G (2005) P2Y purinergic receptors regulate the growth of human melanomas. Cancer Lett 224:81–91
Allman R, Cowburn P, Mason M (2000) In vitro and in vivo effects of a cyclic peptide with affinity for the ανβ3 integrin in human melanoma cells. Eur J Cancer 36:410–422. doi:10.1016/S0959-8049(99) 00279-8
Gershwin ME, Ikeda RM, Kawakami RG, Owens RB (1977) Immunobiology of heterotransplanted human tumors in nude mice. J Natl Cancer Inst 58:1455–1461
Rapaport E, Fontaine J (1989) Generation of extracellular ATP in blood and its mediated inhibition of host weight loss in tumor-bearing mice. Biochem Pharmacol 38:4261–4266. doi:10.1016/0006-2952(89) 90524-8
Giard DJ, Aaronson SA, Todaro GJ, Arnstein P, Kersey JH, Dosik H, Parks WP (1973) In vitro cultivation of human tumors: establishment of cell lines derived from a series of solid tumors. J Natl Cancer Inst 51:1417–1423
United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) (1998) Guidelines for the welfare of animals in experimental neoplasia (Second Edition). Br J Cancer 77:1–10
Amizuka N, Warshawsky H, Henderson JE, Goltzman D, Karaplis AC (1994) Parathyroid hormone-related peptide-depleted mice show abnormal epiphyseal cartilage development and altered endochondral bone formation. J Cell Biol 126:1611–1623. doi:10.1083/jcb.126.6.1611
Gavrieli Y, Sherman Y, Ben-Sasson SA (1992) Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 119:493–501. doi:10.1083/jcb.119.3.493
Fidler IJ (1973) Selection of successive tumour lines for metastasis. Nat New Biol 242:148–149
Ishikawa M, Fernandez B, Kerbel RS (1988) Highly pigmented human melanoma variant which metastasizes widely in nude mice, including to skin and brain. Cancer Res 48:4897–4903
Vad NM, Yount G, Moore D, Weidanz J, Moridani MY (2009) Biochemical mechanism of acetaminophen (APAP) induced toxicity in melanoma cell lines. J Pharm Sci 98:1409–25
Rapaport E, Fontaine J (1989) Anticancer activities of adenine nucleotides in mice are mediated through expansion of erythrocyte ATP pools. Proc Natl Acad Sci USA 86:1662–1666. doi:10.1073/pnas.86.5.1662
Rapaport E (1988) Experimental cancer therapy in mice by adenine nucleotides. Eur J Cancer Clin Oncol 24:1491–1497. doi:10.1016/0277-5379(88) 90340-9
Gaba SJ, Bourgouin-Karaouni D, Dujols P, Michel FB, Prefaut C (1986) Effects of adenosine triphosphate on pulmonary circulation in chronic obstructive pulmonary disease. ATP: a pulmonary vasoregulator? Am Rev Respir Dis 134:1140–1144
Haskell CM, Wong M, Williams A, Lee LY (1996) Phase I trial of extracellular adenosine 5′-triphosphate in patients with advanced cancer. Med Pediatr Oncol 27:165–173. doi:10.1002/(SICI) 1096-911X(199609) 27:3<165::AID-MPO6>3.0.CO;2-C
Agteresch HJ, Dagnelie PV, van der Gaast A, Stijnen T, Wilson JH (2000) Randomized clinical trial of adenosine 5′-triphosphate in patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 92:321–328. doi:10.1093/jnci/92.4.321
Burnstock G (2001) Overview of P2 receptors: possible functions in immune cells. Drug Dev Res 53:53–59. doi:10.1002/ddr.1170
Deli T, Varga N, Adam A, Kenessey I, Rásó E, Puskás LG, Tóvári J, Fodor J, Fehér M, Szigeti GP, Csernoch L, Tímár J (2007) Functional genomics of calcium channels in human melanoma cells. Int J Cancer 121:55–65. doi:10.1002/ijc.22621
Spychala J (2000) Tumor-promoting functions of adenosine. Pharmacol Ther 87:161–173. doi:10.1016/S0163-7258(00) 00053-X
Ohta A, Gorelik E, Prasad SJ, Ronchese F, Lukashev D, Wong MK, Huang X, Caldwell S, Liu K, Smith P, Chen JF, Jackson EK, Apasov S, Abrams S, Sitkovsky M (2006) A2A adenosine receptor protects tumors from antitumor T cells. Proc Natl Acad Sci USA 103:13132–13137. doi:10.1073/pnas.0605251103
Richard CL, Tan EY, Blay J (2006) Adenosine upregulates CXCR4 and enhances the proliferative and migratory responses of human carcinoma cells to CXCL12/SDF-1α. Int J Cancer 119:2044–2053. doi:10.1002/ijc.22084
Hoskin DW, Mader JS, Furlong SJ, Conrad DM, Blay J (2008) Inhibition of T cell and natural killer cell function by adenosine and its contribution to immune evasion by tumor cells. Int J Oncol 32:527–535
Sitkovsky M, Lukashev D, Deaglio S, Dwyer K, Robson SC, Ohta A (2008) Adenosine A2A receptor antagonists: blockade of adenosinergic effects and T regulatory cells. Br J Pharmacol 153(Suppl 1):S457–S464. doi:10.1038/bjp. 2008.23
Fishman P, Bar-Yehuda S, Madi L, Cohn I (2002) A3 adenosine receptor as a target for cancer therapy. Anticancer Drugs 13:437–443. doi:10.1097/00001813-200206000-00001
Madi L, Ochaion A, Rath-Wolfson L, Bar-Yehuda S, Erlanger A, Ohana G, Harish A, Merimski O, Barer F, Fishman P (2004) The A3 adenosine receptor is highly expressed in tumor versus normal cells: potential target for tumor growth inhibition. Clin Cancer Res 10:4472–4479. doi:10.1158/1078-0432.CCR-03-0651
Nakamura K, Yoshikawa N, Yamaguchi Y, Kagota S, Shinozuka K, Kunitomo M (2006) Antitumor effect of cordycepin (3′-deoxyadenosine) on mouse melanoma and lung carcinoma cells involves adenosine A3 receptor stimulation. Anticancer Res 26:43–47
Saitoh M, Nagai K, Nakagawa K, Yamamura T, Yamamoto S, Nishizaki T (2004) Adenosine induces apoptosis in the human gastric cancer cells via an intrinsic pathway relevant to activation of AMP-activated protein kinase. Biochem Pharmacol 67:2005–2011. doi:10.1016/j.bcp. 2004.01.020
White N, Burnstock G (2006) P2 receptors and cancer. Trends Pharmacol Sci 27:211–217. doi:10.1016/j.tips.2006.02.004
Acknowledgements
This work was supported by a research fellowship from The Royal College of Surgeons of England, a research pump-priming grant from the Royal College of Surgeons of Edinburgh and the Paton/Masser research award from the British Association of Plastic Surgeons.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
White, N., Knight, G.E., Butler, P.E.M. et al. An in vivo model of melanoma: treatment with ATP. Purinergic Signalling 5, 327–333 (2009). https://doi.org/10.1007/s11302-009-9156-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11302-009-9156-0